The AML1 transcription factor complex is the most frequent target of leukemia-associated chromosomal translocations. Homeodomain-interacting protein kinase 2 (HIPK2) is a part of the AML1 complex and activates AML1-mediated transcription. However, chromosomal translocations and mutations of HIPK2 have not been reported. In the current study, we screened mutations of the HIPK2 gene in 50 cases of acute myeloid leukemia (AML) and in 80 cases of myelodysplastic syndrome (MDS). Results indicated there were two missense mutations (R868W and N958I) in the speckle-retention signal (SRS) domain of HIPK2. Subcellular localization analyses indicated that the two mutants were largely localized to nuclear regions with conical or ring shapes, and were somewhat diffused in the nucleus, in contrast to the wild type, which were mainly localized in nuclear speckles. The mutations impaired the overlapping localization of AML1 and HIPK2. The mutants showed decreased activities and a dominant-negative function over wild-type protein in AML1-and p53-dependent transcription. These findings suggest that dysfunction of HIPK2 may play a role in the pathogenesis of leukemia.
Introduction
Leukemia is characterized by autonomous proliferation and impaired differentiation of hematopoietic precursor cells, and is considered to be the result of the accumulation of mutations. The mutations associated with the pathogenesis of leukemia include point mutations, gene rearrangements and chromosomal translocations. The AML1 gene is the frequent target of leukemia-associated chromosome translocations, such as t(8;21)(q22;q22) (AML1-MTG8/ETO) (Miyoshi et al., 1991) , t(3;21)(q26;q22) (AML1-EV11/EAP/ MDS1) (Nucifora et al., 1993; Mitani et al., 1994) , t(16;21)(q24;q22) (AML1-MTG16) (Gamou et al., 1998) and t(12;21)(p13;q22) (TEL-AML1) (Golub et al., 1995; Romana et al., 1995) . AML1 protein forms a heterodimer with CBFb and binds to the specific DNA sequence to regulate the expression of a number of hematopoietic genes (Meyers et al., 1993; Ogawa et al., 1993) . Both AML1 and CBFb are essential for the development of all definitive hematopoiesis lineages (Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996a, b; Okada et al., 1998) . AML1 forms complexes with PML and HATs, such as p300/CBP and MOZ, leading to the activation of transcription (Kitabayashi et al., 1998 (Kitabayashi et al., , 2001a Nguyen et al., 2005) . The genes encoding components of the AML1 complex are also the targets of leukemia-associated chromosomal translocations, including t(15;17) (q22;q11.2-q12) (PML-RAR a) (de The et al., 1990 Kakizuka et al., 1991; Kastner et al., 1992) , t(8;22)(p11;q13) (MOZ-p300) (Chaffanet et al., 2000; Kitabayashi et al., 2001b) , t(11;22)(q23;q13) (E1A-p300) (Ida et al., 1997) , t(8;16)(p11;p13) (MOZ-CBP) (Borrow et al., 1996) , t(11;16)(q23;p13) (MLL-CBP) (Satake et al., 1997; Sobulo et al., 1997; Taki et al., 1997) and inv(8)(p11q13)(MOZ-TIF2) (Carapeti et al., 1998 (Carapeti et al., , 1999 . AML1 mutations have been reported in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (Osato et al., 1999; Imai et al., 2000; Preudhomme et al., 2000) . Recently, we found that homeodomain-interacting protein kinase-2 (HIPK2) was both involved in AML1 complex, and in the activation of the AML1 complex (Aikawa et al., 2006) . However, chromosomal translocations and mutations of HIPK2 have not been reported previously.
HIPK2, as well as HIPK1 and HIPK3, is a member of a family of serine/threonine nuclear kinases and localizes to nuclear speckles (Kim et al., 1998; Hofmann et al., 2000; Wang et al., 2001; Moller et al., 2003a) . Previous studies have shown there is binding of HIPK2 to various target proteins Hofmann et al., 2003; Tomasini et al., 2003; Zhang et al., 2003 Zhang et al., , 2005 Moller et al., 2003b; Rui et al., 2004; Wiggins et al., 2004) , with subsequent modulation of the function of these proteins to corepressors or coactivators. HIPK2 regulates gene transcription (Kim et al., 1998; Choi et al., 1999) inhibits cell growth (Pierantoni et al., 2001) and is involved in apoptosis (D'Orazi et al., 2002; Hofmann et al., 2002) . HIPK2 activates p53 function, thereby promoting apoptosis following ultraviolet (UV) treatment (D'Orazi et al., 2002; Hofmann et al., 2002) .
Human HIPK2 has been mapped to chromosome 7q32-q34 (Hofmann et al., 2000; Wang et al., 2001) , which is known to be frequently rearranged in AML, MDS, and in other human neoplasias (Mitelman et al., 1997) . Moreover, HIPK2 expression is reduced in breast and thyroid carcinomas , thus suggesting HIPK2 as a candidate tumor suppressor gene . In the current study, we screened mutations of HIPK2 in AML and MDS using denaturing high performance liquid chromatography (DHPLC). We found two missense mutations (R868W and N958I) within the speckle-retention signal (SRS) region of HIPK2 that were associated with the subcellular localization. These findings suggest HIPK2 may be involved in the pathogenesis of leukemia.
Results

Mutations of HIPK2 gene
In order to search for mutations in all coding exons of the HIPK2 gene, we performed DHPLC analysis and direct sequence analysis. One missense mutation was detected in MDS, namely R868W in exon 12, and one missense mutation was detected in AML, namely N958I in exon 13 (Figure 1) . The leukemic cells with these mutations showed normal karyotypes and no mutations in the AML1 gene (data not shown). We also detected several single-nucleotide polymorphisms or nonsense mutations polymorphisms, none of which have been reported previously (Table 1) .
Subcellular localization of the HIPK2 mutants
The two mutations R868W and N958I were located within the SRS region, which is required for localization of HIPK2 in nuclear speckles Engelhardt et al., 2003) . This suggests that the mutations may affect the localization. To investigate subcellular localization, U2OS cells were transfected with wild type, R868W and N958I mutant of HIPK2. Subsequently, we performed immunofluorescence analysis (Figure 2 ). Wild-type HIPK2 was localized to the small nuclear speckles and these speckles were distributed within the nucleus. However, R868W and N958I mutants exhibited conical or ring shapes, and were diffused in the nucleus.
The HIPK2 mutants fail to colocalize with AML1b
In order to examine whether the HIPK2 mutants are colocalized with AML1b, U2OS cells were co-transfected with FLAG-tagged AML1b and HAtagged wild type or mutants of HIPK2 (Figure 3 ). Without cotransfection of HIPK2, AML1b was diffused in the nucleus. When coexpressed with HIPK2, AML1b was localized to the nuclear dot structures. Moreover, partial overlapping with wild-type HIPK2 was also observed. In contrast, the two mutants of the HIPK2 proteins, R868W and N958I, were not detected overlapping the localization of AML1b.
HIPK2 forms a ternary complex with AML1b and p300, and phosphorylates AML1b and p300 (Aikawa et al., 2006) . Therefore, we also investigated whether HIPK2 mutants can interact with and phosphorylate AML1b and p300 (Supplementary Figure 1) . No significant differences in interaction or phosphorylation were observed between the wild type and the HIPK2 mutants.
Transcription activation abilities of the HIPK2 mutants Our data suggest that HIPK2 plays an important role in AML1-mediated and p300-mediated transcription. (Aikawa et al., 2006) . To analyse effects of these mutants on transcription activation, reporter experiments were performed. As shown in Figure 4a and b, AML1-mediated and p300-mediated transcription was strongly activated by wild-type HIPK2, but not by the mutants R868W and N958I. These findings suggest that the two HIPK2 mutants lacked transactivation potential.
To determine if the SRS domain is required in order for HIPK2 to stimulate AML1-mediated transcription activation, a series of HIPK2 deletion mutants were constructed and tested for AML1-mediated transactivation. As shown in Figure 5 , deletion of the C-terminal region to amino-acid position 1026 did not inhibit but rather stimulated the transactivation. However, further deletion to position 860 completely inhibited the transactivation. These results suggest that the SRS domain is required for HIPK2-mediated transactivation.
Effect of the HIPK2 mutants on p53 activity HIPK2 phosphorylates p53 on Ser46, resulting in activation of p53-dependent transcription, cell growth regulation and apoptosis initiation (D'Orazi et al., 2002; Hofmann et al., 2002) . To determine whether HIPK2 mutants modulate the transcriptional activity of p53, H1299 cells were co-transfected with the MDM2 promoter and expression vectors encoding p53 and HIPK2 (WT, KD, R868W, N958I). As shown in Figure 6a , p53-dependent transcription was strongly activated by wild-type HIPK2, but not by the mutants R868W and N958I.
To investigate whether HIPK2 affects DNA damageinduced expression of endogenous MDM2, MCF7 cells were transfected with HIPK2 (WT, KD, R868W, N958I) and were exposed to UV. As shown in Figure 6b , expression of MDM2 was increased by wild-type HIPK2, but not by the mutants R868W, N958I and KD. Taken together, these experiments suggest that two HIPK2 mutants affect the p53 pathway.
HIPK2 mutants act as dominant-negative effects in a luciferase assay In order to investigate whether two HIPK2 mutants exhibit a dominant-negative function, wild-type HIPK2 were co-transfected with the HIPK2 mutants. As shown in Figure 7 , the mutants R868W and N958I repressed the wild-type HIPK2-induced activation of both AML1-mediated and p53-mediated transcription in dose-dependent manners. These findings suggest that the two HIPK2 mutants exhibit a dominant-negative function over wildtype HIPK2.
Discussion
Genetic mutations, such as point mutations, gene rearrangement and chromosomal translocations, have been considered to be associated with the pathogenesis of leukemia. The genes encoding AML1 and/or its binding factors are frequent targets of the mutations or chromosome translocations associated with AML and MDS. We have found that HIPK2 is a part of the AML1 complex and is capable of stimulating AML1-mediated transcription activation (Aikawa et al., 2006) . Colocalization of HIPK2 (wild type, the mutants R868W and N958I) with AML1b. U2OS cells were co-transfected with Flag-AML1b and HA-tagged HIPK2 WT, R868W or N958I. Cells were fixed 24 h later and proteins were detected by indirect immunofluorescence staining that used rabbit anti-AML1 and rat anti-HA as primary antibodies. Localization of AML1b is indicated by the red signal, and HIPK2 is indicated by the green signal. Overlapping localization is shown in yellow. DNA was stained with DAPI.
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These findings suggest that HIPK2 may be also the target of leukemia-associated mutations/chromosome aberrations. However, there have been no previous reports of mutation/chromosome abnormalities in the HIPK2 gene. In the present study, we examined mutations of the HIPK2 gene in 50 cases of AML and in 80 cases of MDS. Analyses indicated that there were two missense mutations (R868W and N958I) in the SRS domain of HIPK2. The HIPK2 gene is mapped to the human chromosome 7q32-q34. Deletion of 7q is frequently found in AML and MDS. Initially, we expected mutation of HIPK2 to occur in patients with the 7q deletion, thereby resulting in a homozygous loss of functional HIPK2. However, no mutations were found in these types of patients. As a matter of fact, patients with HIPK2 mutations showed normal karyotypes and did not have any other mutations in AML1. These results suggest that the mutation of HIPK2 plays a role similar to chromosome translocations and AML1 mutations in the pathogenesis of leukemia. However, further analysis is required to confirm this hypothesis.
Recently, we found that HIPK2 interactions result in the phosphorylation of AML1 and p300 leading to stimulation of AML1-mediated transcription (Aikawa et al., 2006) . The two missense mutants that we identified here (R868W and N958I) showed decreased activities and a dominant-negative function over wild-type protein in AML1-and p53-dependent Cell lysates were prepared 24 h after transfection and were analysed for luciferase activity. (b) 293 T cells were transfected with 500 ng of pFR-luc (Gal4-luc), 100 ng of Gal4-p300, 400 ng of wild type or the mutants R868W, N958I of HIPK2 and 2 ng of phRL-CMV. Cell lysates were prepared 24 h after transfection and were analysed for luciferase activity. transcription. However, the R868W and N958I mutants affect neither the kinase activity nor interaction with AML1 and p300. The R868W and N958I mutations were found in the SRS domain, in contrast to the kinase domain, for which no mutations were detected. Since SRS is reportedly associated with the HIPK2 localization to nuclear speckles Engelhardt et al., 2003) , SRS mutations may affect localization of HIPK2. In fact, R868W and N958I mutations showed impaired localization of HIPK2 in the nuclear speckles. In both wild-type HIPK2 and in AML1, there was colocalization in the nuclear speckles. However, when there were mutations of HIPK2, the overlapping localization was disrupted. Deletion analysis of HIPK2 indicated that the SRS domain is required for HIPK2 to be able to stimulate AML1-mediated transcription activation. These data suggest that the mutations destabilize the localization of HIPK2, leading to dysfunction of the AML1 transcription factor complex.
The mechanism for regulation of the HIPK2 localization to the nuclear speckles via the SRS is poorly understood. Previous studies indicated that HIPK2 is modified by a small ubiquitin-like modifier 1 (SUMO-1) , and that SUMO modification of HIPK2 occurs at lysine 25 (Hofmann et al., 2005; Sung et al., 2005) . The SRS contains a domain that interacts with a SUMO-conjugating (E2) enzyme, mUBC9 . When there is SUMO modification of HIPK2, this affects localization to the nuclear speckles Engelhardt et al., 2003) . It has been reported that SUMO modification regulates localization and activity of target proteins such as RanGAP (Matunis et al., 1996 (Matunis et al., , 1998 Mahajan et al., 1997) , PML (Kamitani et al., 1998; Duprez et al., 1999) and CtBP (Lin et al., 2003) . However, no differences in SUMO modification were observed between the wildtype and HIPK2 mutants (Supplementary Figure 2) . Further biological studies are necessary to clarify how this localization of HIPK2 is regulated by SRS.
We recently found that the Hipk1/Hipk2-deficient mice exhibit defects in definitive hematopoiesis (Aikawa et al., 2006) . We also found that expression levels of HIPK2 increase during granulocyte-colony stimulating factor (G-CSF)-induced differentiation of myeloid cells. These results suggest that HIPK2 plays a role in myeloid cell hematopoiesis and differentiation. Therefore, HIPK2 mutation may lead to impairment of hematopoiesis and/or differentiation of myeloid cells, resulting in the pathogenesis of leukemia. 
Inactivation of the p53 pathway is associated with cancer development. Although p53 mutations are observed in more than 50% in solid tumors, p53 mutations are found in only 17 and 10% of AML and MDS cases, respectively (Krug et al., 2002) , suggesting that leukemia can develop even in the presence of normal p53. In fact, no mutations in p53 were detected in two patients, with HIPK2 mutations. It has been reported that HIPK2 is involved in induction of p53-dependent transcription, cell cycle and apoptosis (D'Orazi et al., 2002; Hofmann et al., 2002) . In this study, we found that HIPK2 mutants exhibited impaired activation of p53-mediated transcription as well as AML1-mediated transcription. Thus, we believe that HIPK2 mutations affect both AML1-mediated cell differentiation and p53-mediated apoptosis to induce leukemia.
In summary, within the SRS, we found two mutations of the HIPK2 gene, R868W and N958I, which are associated with the subcellular localization of HIPK2. These mutations impaired overlapping localization of AML1 and HIPK2, as well as the activation of AML1-mediated transcription by HIPK2. Furthermore, the two mutants decreased p53-mediated transcriptional activity. Therefore, our results provide new evidence on a possible mechanism for the pathogenesis of leukemia.
Materials and methods
Patient samples
We examined 80 cases of MDS (31 refractory anemia with excess blasts (RAEB), 19 RAEB in transformation (RAEBt), 30 AML following MDS) and 50 cases of AML without antecedent MDS (4 M0, 13 M1, 9 M2, 9 M4, 12 M5, 2 M6, 1 M7) for screening mutations of HIPK2. All of these patients were diagnosed by morphology, immunophenotype, karyotype and AML1 mutation analysis as described previously (Harada et al., 2004) . Patients with t(15;17), t(8;21), inv(16) or AML1 point mutation were excluded from this analysis. Patient samples were taken after obtaining informed consent and approval from the institutional review board at Hiroshima University.
Screening for HIPK2 mutations Genomic DNA was isolated, and genomic fragments were amplified by PCR using 18 sets of primers ( Table 2 ). The PCR reaction was performed for 35 cycles in a 10 ml mixture containing genomic DNA, 1 ml of 10 Â PCR buffer, 0.25 ml of 10 mM dNTP, 2 pmol of each primer and 0.07 U Taq polymerase. Each PCR cycle consisted of 941C for 20 s, 56-601C for 40 s and 721C for 1 min, followed by a final extension at 721C for 10 min. PCR products were electrophoresed in 2% agarose gels. Mutation screening for HIPK2 was carried out by prescreening with DHPLC analysis (WAVE DNA Fragment Analysis System, Transgenomic, Omaha, NE, USA). If an abnormal peak sample was detected, it was directly sequenced using a Big Dye Terminator Sequencing kit and ABI Prism 3100 Genetic Analyzer.
Cell culture and transfection SaOS2, 293T, U2OS, MCF7 and H1299 cells were cultured in Dulbecco's modified Eagle's medium or RPMI supplemented with 10% fetal calf serum (FCS) at 371C and 5% CO 2 . U2OS and MCF7 cells were transfected by Effectene (Qiagen, Hilden, Germany) according to the manufacturer's instructions. For the reporter assay, 293T, SaOS2 and H1299 cells were transfected by the calcium phosphate precipitation method.
Plasmids
The human AML1b expression vector pLUCX-FLAGAML1b, human p300 expression vector pLUCX-FLAGp300, human MOZ expression pLUCX-FLAG-MOZ, human HIPK2 expression vector pLUCX-HA-HIPK2, pLUCX-HA-HIPK2 KD, human p53 expression vector pLUCX-FLAGp53, MDM2-luc and MPO-luc have been described previously (Kitabayashi et al., 2001a; Aikawa et al., 2006) . The expression vectors of the HIPK2 mutants, LUCX-HA-HIPK2 R868W, LUCX-HA-HIPK2 N958I, were generated by site-specific mutagenesis using overlapping extension PCR. The sequences of these constructs were checked by DNA sequencing. 
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Immunofluorescence analysis U2OS cells were grown in four-well chamber slides and cotransfected with various expression vectors. Twenty-four hours after being co-transfected, cells were fixed for 10 min with 4% paraformaldehyde at room temperature, then permeabilized with 0.1% Triton-X 100 in phosphate-buffered saline (PBS) for 10 min. Next, cells were washed three times with PBS and blocked with 0.2% FCS at 41C for overnight. Cells were incubated with primary antibodies in PBS containing 0.2% FCS for 1 h at room temperature. Cellular nuclei were stained by 4 0 ,6-diamidino-2-phenylindole (DAPI). Images under a fluorescence microscope (Olympus, Melville, NY, USA) were captured with a CoolSNAP-HQ CCD camera (Roper Scientific, Ottobrunn, Germany) at a magnification of Â 60.
Luciferase assay SaOS2, 293T or H1299 cells were co-transfected with various expression vectors in 24-well plates, and luciferase activity was assayed after 24 h using a luminometer Lumat LB9507 (Berthold, Bad Wildbad, Germany) according to the manufacturer's protocol (Promega, Madison, WI, USA). Results of reporter assays represent the average values for relative luciferase activity generated from three independent experiments that were normalized using the activity of the enzyme from phRL-CMV as an internal control.
Immunoprecipitation, immunoblotting and antibodies
For immunoprecipitation experiments, cell were lysed in a lysis buffer containing 250 mM NaCl, 20 mM sodium phosphate pH 7.0, 30 mM sodium pyrophosphate, 10 mM NaF, 0.1% NP-40, 5 mM dithiothreitol, 1 mM phenylmethylsulphonylfluoride and protease inhibitor. Cell lysates were incubated with anti-FLAG antibody-conjugated agarose beads (Sigma, St Louis, MO, USA) and slightly rotated at 41C overnight. The absorbed beads were washed three times with lysis buffer. Precipitated proteins were eluted from the beads by FLAG peptide and dissolved with the same volume of 2 Â sodium dodecyl sulfate (SDS) sample buffer. When immunoprecipitation was not performed, total protein lysates were prepared in 2 Â SDS sample buffer. Antibodies were detected by chemiluminescence using ECL plus Detection Reagents (Amersham Biosciences, Buckinghamshire, UK). The primary antibodies used in this study were anti-FLAG (M2) (Sigma), anti-HA (3F10) (Roche, Basel, Switzerland), anti-human AML rabbit polyclonal, and anti-p300 rabbit polyclonal (N15) antibodies. HIPK2 mutations in AML and MDS X-L Li et al
